Skip to content
Study details
Enrolling now

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Mayo Clinic
NCT IDNCT06972056ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

1,335

Study length

about 4.4 years

Ages

18–70

Locations

23 sites in AZ, CA, CO +15

What this study is about

This trial is testing the effectiveness of three migraine preventive medications: atogepant, propranolol, and topiramate. Participants will be randomly assigned to take one of these medications for 1606 days while tracking their headaches with a daily diary.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Atogepant 60 mg
  • 2.Take Propranolol 160 mg
  • 3.Take Topiramate 100 mg

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

atogepant, propranolol (Non-selective beta blocker; slows heart rate), topiramate

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Medication-Related Adverse Events, Migraine Specific Quality-of-Life - Role Function-Restrictive

Body systems

Neurology